Bromobenzene

Bromobenzene

SCHEMBL129999

Brc1ccccc1.C1CCOC1.[MgH2]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPK1 P28482 1/20 0.40
LMNA P02545 5/20 0.38
CRHBP P24387 2/20 0.37
CRHR2 Q13324 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
MGLL Q99685 2/20 0.36
ORAI1 Q96D31 1/20 0.36
ORAI2 Q96SN7 1/20 0.36
ORAI3 Q9BRQ5 1/20 0.36
TRPV6 Q9H1D0 1/20 0.36
MAPT P10636 4/20 0.36
KMT2A Q03164 3/20 0.36
MPI P34949 1/20 0.36
BLM P54132 1/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1B1 Q16678 1/20 0.34
CYP2A13 Q16696 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromobenzene SCHEMBL14795351 0.97 ALDH1A1 (0.58) ALDH1A1TDP1MAPK1LMNACRHBP
Bromobenzene SCHEMBL17609144 0.87 ALDH1A1 (0.65) ALDH1A1TDP1MAPK1LMNACRHBP
Bromobenzene SCHEMBL28202175 0.85 ALDH1A1 (0.44) ALDH1A1TDP1MAPK1LMNASMN1; SMN2
Tetrahydrofuran SCHEMBL28059145 0.84 ALDH1A1 (0.65) ALDH1A1TDP1MAPK1SMN1; SMN2MGLL
Bromobenzene SCHEMBL27149738 0.82 ALDH1A1 (0.58) ALDH1A1TDP1MAPK1LMNASMN1; SMN2
Bromobenzene SCHEMBL704553 0.82 ALDH1A1 (0.58) ALDH1A1TDP1MAPK1LMNASMN1; SMN2
Bromobenzene SCHEMBL29291356 0.82 ALDH1A1 (0.41) ALDH1A1TDP1MAPK1LMNASMN1; SMN2
Tetrahydrofuran SCHEMBL28193777 0.80 HTT (0.43) ALDH1A1TDP1MAPK1LMNASMN1; SMN2
Bromobenzene SCHEMBL28753154 0.78 ALDH1A1 (0.79) ALDH1A1TDP1MAPK1SMN1; SMN2MAPT
Bromobenzene SCHEMBL29116318 0.78 ALDH1A1 (0.92) ALDH1A1TDP1MAPK1SMN1; SMN2ORAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed
CN-1283612-C Process for producing 4-phenyl-4-oxo-2-butenoic ester derivative SANKIO CHEMICAL CO LTD (JP) 2006-11-08 CN disclosed
CN-1653030-A Method for producing 4-phenyl-4-oxo-2-butenoate derivative SANKIO CHEMICAL CO LTD (JP) 2005-08-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 ALDH1A1 580/4885TDP1 4125/4885MAPK1 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.